Iindaba

I-NEW DELHI, i-22 kaJuni (Xinhua) - umenzi wokugonya wase-Indiya u-Bharat Biotech's Covaxin ubonise ukusebenza kwe-77.8 yeepesenti kwizilingo zesigaba se-III, amajelo asekuhlaleni abika ngoLwesibini.

"I-Bharat Biotech's Covaxin isebenza ngeepesenti ezingama-77.8 ekukhuseleni i-COVID-19, ngokwedatha evela kuvavanyo lwesigaba III olwenziwe kubathathi-nxaxheba abangama-25,800 kulo lonke elaseIndiya," yatsho ingxelo.

Izinga lokuphumelela liphume ngoLwesibini emva kokuba ikomiti yeengcali ze-Drugs Controller of India (DCGI) (SEC) yadibana kwaye yaxoxa ngeziphumo.

Ifemu exuba amayeza ingenise idatha yolingo lwesigaba sesi-III yesitofu sokugonya kwi-DCGI ngempelaveki.

Iingxelo zithi inkampani kulindeleke ukuba ibambe intlanganiso "yokungeniswa kwangaphambili" kunye nabasemagunyeni beWorld Health Organisation ngoLwesithathu, ukuxoxa ngezikhokelo zokungeniswa kokugqibela kwedatha kunye namaxwebhu afunekayo.

I-Indiya yaqala ugonyo oluninzi ngokuchasene ne-COVID-19 ngoJan. 16 ngokufaka izitofu ezimbini ezenziwe eIndiya, ezizezi, iCovishield kunye neCovaxin.

I-Serum Institute of India (SII) yenza i-AstraZeneca-Oxford University's Covishield, ngelixa i-Bharat Biotech ihlangene ne-Indian Council of Medical Research (ICMR) ekwenzeni i-Covaxin.

Isitofu sokugonya seSputnik V esenziwe eRussia sasasazwa kweli lizwe.Enditem